Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
Mar 15, 2023 · Eligible patients with moderate-to-severe atopic dermatitis (adults [≥18 years of age] and adolescents [12 to <18 years of age, weighing ≥40 kg]) were randomly assigned in a 2:1 ratio to ...
FDA Extends Review of Tapinarof Cream for Atopic Dermatitis
1 day ago · The new PDUFA target date is March 12, 2025. The Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for tapinarof cream, 1% in the treatment of atopic dermatitis in adults and children aged 2 years and older. Tapinarof is an aryl hydrocarbon receptor agonist currently marketed ...
Atopic dermatitis - Latest research and news | Nature
Nov 6, 2024 · Atopic dermatitis, also known as atopic eczema, is a chronic inflammatory familial disease of the skin. It is characterized by an increased ability to form immunoglobulin E and a tendency to...
Atopic dermatitis: New drug significantly improves symptoms
Sep 23, 2024 · For people with atopic dermatitis, a new drug targeting the condition has just been approved by the FDA. The drug, from Eli Lilly, inhibits the action of a cytokine believed to be the primary...
Atopic dermatitis: an expanding therapeutic pipeline for a ...
Aug 20, 2021 · Atopic dermatitis (AD) is a common chronic inflammatory skin disease with a complex pathophysiology that underlies a wide spectrum of clinical phenotypes. AD remains challenging to treat owing...
New Treatment for Moderate to Severe Atopic Dermatitis ...
(December 09, 2022) Patients with moderate to severe atopic dermatitis who participated in a clinical trial of rocatinlimab—a novel, patient-tailored monoclonal antibody therapy—showed promising results both while taking the drug and up to 20 weeks after the therapy was stopped, Mount Sinai researchers reported in The Lancet.
U.S. FDA Approves RINVOQ® (upadacitinib) to Treat ... - News
Jan 14, 2022 · Across the three atopic dermatitis pivotal studies, RINVOQ (15 mg and 30 mg, once daily) monotherapy and with topical corticosteroids met all primary and secondary endpoints at week 16, with some patients achieving higher levels of skin clearance (EASI 90 and 100).
Atopic dermatitis (eczema) guidelines: 2023 American ...
The purpose of these guidelines is to provide evidence-based recommendations about optimal management of atopic dermatitis (AD; [atopic] eczema) in infants, children, and adults. The guidelines address the following 5 main management questions:
Atopic Dermatitis | New England Journal of Medicine
Mar 24, 2021 · Atopic dermatitis is one of the most prevalent inflammatory skin diseases. It usually develops in childhood and may persist into adulthood; less frequently, it starts in midlife or late life....
Update on FDA Review of VTAMA - Business Wire
Nov 5, 2024 · Atopic dermatitis (AD), commonly referred to as eczema, is one of the most common inflammatory skin diseases, affects over 26 million people in the U.S. alone and up to 10% of adults worldwide.